Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
- Category: Antibodies
- Published on Wednesday, 01 April 2020 12:57
- Hits: 2906
- Multiple highly potent, neutralizing antibodies already identified from convalesced patients
- First-in-human trials planned for third quarter this year
BEIJING, China & DURHAM, NC, USA I March 31, 2020 I Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences (“Brii Bio”) today announced a partnership and license agreement to discover, develop, manufacture and commercialize fully human neutralizing monoclonal antibodies to address the global pandemic of COVID-19.
Researchers in the laboratories of Professor Linqi Zhang at Tsinghua University and Professor Zheng Zhang at 3rd People’s Hospital of Shenzhen have identified multiple diverse and potent neutralizing monoclonal antibodies with therapeutic potential against SARS CoV-2 that have been characterized from patients in China who have recovered from COVID-19. Tsinghua and 3rd People’s Hospital of Shenzhen published the results of their discovery research in the preprint server BioRxiv. Based on this research, the university and hospital, together with Brii Bio, intend to advance multiple candidates for prophylactic and therapeutic intervention.
“We have been able to move very quickly by virtue of our proximity to the initial outbreak and our expertise from prior research in SARS and MERS,” said Professor Linqi Zhang, Tsinghua University. “Our investigators have worked day and night since the beginning of the outbreak. With Brii Bio joining and the dedicated focus afforded by this new venture, we expect to accelerate our development efforts with the shared goal of bringing forward an effective therapy to benefit people around the world affected by this pandemic.”
“Since the beginning of the outbreak, our hospital had responded urgently to focus on searching for monoclonal antibodies against COVID-19. Our teams worked extremely hard and isolated hundreds of monoclonal antibodies early on through single B-cell sorting and rapid sequencing, thereby laying the foundation for further optimization of these neutralizing antibodies,” commented Professor Zheng Zhang, 3rd People’s Hospital of Shenzhen. “Our partnership with Tsinghua and Brii Bio will accelerate the development of these neutralizing antibodies to the clinic and may help to slow down the spread of the COVID-19 pandemic.”
“Our collaboration with Tsinghua University and 3rd People’s Hospital of Shenzhen perfectly aligns with Brii Bio’s mission to make significant contributions to public health throughout the world,” said Zhi Hong, Ph.D., CEO of Brii Bio. “With a shared vision, the collaboration marries the abilities of Tsinghua University and 3rd People’s Hospital of Shenzhen to rapidly discover antibodies against SARS-CoV-2 with Brii Bio’s development expertise in infectious diseases to create an innovative collaboration model and bring the best people together to address the current public health challenge and ones to come.”
Through this effort, Tsinghua, 3rd People’s Hospital of Shenzhen and Brii Bio seek to achieve an accelerated timeline of six months from the selection of a lead development candidate to the first-in-human clinical trials, with the potential for additional timeline acceleration. Tsinghua and collaborators at 3rd People’s Hospital of Shenzhen will provide capabilities and researchers to ensure all necessary testing, screening, virologic, biochemical and cell culture characterizations. Brii Bio will provide development expertise, antibody optimization, intellectual protection, project management, CDMO management, and clinical and regulatory oversight.
About Tsinghua University
Tsinghua University was established in 1911 under the name “Tsing Hua Imperial College.” Tsinghua is an important hub for scientific research and talent cultivation. For more than 100 years with the goal of leading global fundamental research and serving core national development strategies, Tsinghua University is dedicated to optimizing scientific discipline and academic settings and promoting innovation capabilities for top-notch research outcomes.
About Shenzhen No.3 People’s Hospital
National Clinical Research Center for Infectious Diseases / Third People's Hospital of Shenzhen (Second Affiliated Hospital of Southern University of Science and Technology) was founded in 1985, formerly known as "Shenzhen Donghu Hospital", which was then renamed in 2008. The hospital is a modern Class 3A research hospital founded by the Shenzhen Municipal Government under the “comprehensive general hospital with strong specialty focus” guiding principle. The hospital is mainly responsible for the prevention and control of infectious diseases and major epidemics in Shenzhen and surrounding areas, and provides comprehensive general medical services. It is the most comprehensive and largest infectious disease general hospital in southern China. The Third People's Hospital of Shenzhen is committed to the clinical diagnosis, treatment and research of major infectious diseases with a long history, with extensive experience in major epidemics such as SARS, H5N1 and H9N1 avian influenza, MERS, and SAR-CoV-2, where the hospital had undertaken major clinical diagnosis and treatment tasks, and established systematic systems in diagnosis, treatment and research.
About Brii Biosciences
Brii Biosciences (Brii Bio) is committed to serving patients' needs and improving public health by accelerating the development and delivery of breakthrough medicines through partnerships, best-in-class research and development, and the disruptive application of digital and data insight. With operations in the People's Republic of China and the United States, the company is poised to serve as a bridge to carry transformative medicines to patients, help create significant growth for our partners and establish an innovation engine to help improve the health and wellbeing of patients around the world. The company is developing treatments for illnesses with significant public health burdens, including infectious diseases, liver diseases, and other illnesses. For more information, visit www.briibio.com.
SOURCE: Brii Biosciences